Bal Pharma Ltd

Bal Pharma's capital structure is characterized by a high debt-to-equity ratio of 1.94, indicating a significant reliance on debt financing. The company's liquidity position is moderate, with a current ratio of 1.07 and only INR 80.5 million in cash and equivalents. Free cash flow is negative at INR -36.9 million, suggesting that capital expenditures are outpacing operating cash flow. Profitability metrics show a return on equity of 9.32%, which is relatively strong, but the return on assets of 2.15% is weak, indicating that the company is not efficiently utilizing its assets to generate returns. These figures should be compared to the industry median for a more comprehensive assessment of performance. The company's revenue is derived from a diverse range of pharmaceutical products and APIs, with exports to over 20 countries. However, the financial data does not provide a breakdown of revenue by segment or geography, making it difficult to assess concentration risk or growth drivers. Looking ahead, the company's growth trajectory is uncertain. The financial snapshot does not include revenue history or outlook data, which would be necessary to evaluate future performance. The absence of segment-specific growth projections further limits the ability to forecast revenue trends. Risk factors include a medium liquidity risk due to the company's negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported. However, the company's high debt load could pose credit risk if cash flow does not improve. Recent events and filings are not detailed in the provided data, so no specific recent developments can be cited. The company's financial health and strategic direction would benefit from a more detailed review of recent disclosures and market activities.